Oppenheimer Asset Management Inc. Sells 3,974 Shares of Glaukos Co. (NYSE:GKOS)

Oppenheimer Asset Management Inc. cut its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 21.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,680 shares of the medical instruments supplier's stock after selling 3,974 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Glaukos were worth $1,913,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in GKOS. Values First Advisors Inc. acquired a new stake in Glaukos in the 3rd quarter worth about $25,000. GAMMA Investing LLC lifted its position in Glaukos by 68.8% in the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock valued at $141,000 after purchasing an additional 486 shares during the period. Fifth Third Wealth Advisors LLC acquired a new position in Glaukos during the second quarter worth about $187,000. Procyon Advisors LLC purchased a new stake in shares of Glaukos in the third quarter valued at $210,000. Finally, Brighton Jones LLC acquired a new stake in shares of Glaukos in the second quarter worth $208,000. 99.04% of the stock is currently owned by institutional investors.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of the business's stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total value of $646,800.00. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $13,216,581.84. The trade was a 4.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of the business's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company's stock, valued at approximately $4,225,345.12. This represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,275 shares of company stock worth $1,354,967 over the last three months. Company insiders own 6.40% of the company's stock.

Glaukos Stock Down 0.1 %

GKOS traded down $0.18 during trading on Friday, reaching $138.44. 336,730 shares of the stock were exchanged, compared to its average volume of 611,885. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock's 50 day moving average price is $130.92 and its two-hundred day moving average price is $122.40. Glaukos Co. has a twelve month low of $59.22 and a twelve month high of $145.84.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company had revenue of $96.70 million during the quarter, compared to analysts' expectations of $91.50 million. During the same quarter in the previous year, the business posted ($0.50) earnings per share. Glaukos's quarterly revenue was up 23.9% on a year-over-year basis. Equities analysts forecast that Glaukos Co. will post -1.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Piper Sandler set a $140.00 price target on Glaukos in a report on Thursday, October 17th. Wells Fargo & Company increased their price target on Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Truist Financial increased their target price on shares of Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Needham & Company LLC boosted their price target on shares of Glaukos from $131.00 to $137.00 and gave the stock a "buy" rating in a research report on Thursday, August 1st. Finally, Stifel Nicolaus boosted their target price on Glaukos from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $134.55.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.